Results 61 to 70 of about 30,445,587 (352)

A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice

BMC Cancer, 2019
Background NY-BR-1 has been described as a breast cancer associated differentiation antigen with intrinsic immunogenicity giving rise to endogenous T and B cell responses.
Krishna Das, David Eisel, Mathias Vormehr, Karin Müller-Decker, Adriane Hommertgen, Dirk Jäger, Inka Zörnig, Markus Feuerer, Annette Kopp-Schneider, Wolfram Osen, Stefan B. Eichmüller   +10 more
doaj   +1 more source

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer.

Annual Review of Immunology, 2019
Exhausted CD8 T (Tex) cells are a distinct cell lineage that arise during chronic infections and cancers in animal models and humans. Tex cells are characterized by progressive loss of effector functions, high and sustained inhibitory receptor expression,
Laura M. McLane, Mohamed S. Abdel-Hakeem, E. Wherry   +2 more
semanticscholar   +1 more source

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine, Ofélie Trudeau‐Ferrin, Caroline Laverdière, Patrick Hamel, Rosanne Superstein, Bénédicte Koukoui, Carole Provost, Paul C. Nathan, Vijay Ramaswamy, Furqan Shaikh, Brenda Gallie, Ashwin Mallipatna, Stephanie Kletke, Helen Dimaras, Hallie Coltin   +14 more
wiley   +1 more source

Sphinganine recruits TLR4 adaptors in macrophages and promotes inflammation in murine models of sepsis and melanoma

Nature Communications
After recognizing its ligand lipopolysaccharide, Toll-like receptor 4 (TLR4) recruits adaptor proteins to the cell membrane, thereby initiating downstream signaling and triggering inflammation.
Marvin Hering, Alaa Madi, Roger Sandhoff, Sicong Ma, Jingxia Wu, Alessa Mieg, Karsten Richter, Kerstin Mohr, Nora Knabe, Diana Stichling, Gernot Poschet, Felix Bestvater, Larissa Frank, Jochen Utikal, Viktor Umansky, Guoliang Cui   +15 more
doaj   +1 more source

CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. [PDF]

, 1992
Engagement of the CD3/T cell antigen receptor complex on small, resting T cells is insufficient to trigger cell-mediated cytotoxicity or to induce a proliferative response.
Azuma, M, Buck, D, Cayabyab, M, Lanier, LL, Phillips, JH   +4 more
core   +1 more source

Notch signaling during human T cell development [PDF]

, 2012
Notch signaling is critical during multiple stages of T cell development in both mouse and human. Evidence has emerged in recent years that this pathway might regulate T-lineage differentiation differently between both species.
A Galy, A Krueger, A Sambandam, A Wilson, A Wolfer, AC Jaleco, AI Garbe, AP Weng, B Blom, B Reizis, B Vandekerckhove, BN Weber, C Benne, CC Tydell, CN Ting, D Hockemeyer, D Hockemeyer, E Robey, EM Six, ES David-Fung, F Klein, F Radtke, F Radtke, F Timmermans, F Weerkamp, F Weerkamp, G Awong, H Hirata, H Neves, H Wang, HT Petrie, HY Kueh, I Hoebeke, I Maillard, I Maillard, I Walle Van de, I Walle Van de, J Buer, J Gotter, J Plum, J Shi, JS Yuan, K Heinzel, K Hozumi, K Li, K Maki, K Tanigaki, L Li, M Ciofani, M Ciofani, M Ciofani, M Garcia-Peydro, M Ghisi, M Magri, M Smedt De, M Smedt De, M Smedt De, M Smedt De, MA Yui, MD Green, ML Joachims, N Lefort, P Beatus, P Doerfler, P Li, QL Hao, QL Hao, R Haddad, RN Motte-Mohs La, S Coppernolle Van, S Doulatov, S Gonzalez-Garcia, S Suliman, S Verbeek, SK Durum, SK Ye, SM Lehar, SY Lee, T Hosoya, T Ikawa, T Ikawa, T Kreslavsky, T Kreslavsky, T Palomero, T Taghon, T Taghon, T Taghon, T Taghon, T Taghon, T Taghon, TB Feyerabend, TM Schmitt, TN Taghon, W Dontje, WA Dik, Y Wu, YR Carrasco, Z Galic   +97 more
core   +2 more sources

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Avidity-optimized TCR-T cells target KRAS neoantigens for potent cancer clearance and tumor microenvironment remodeling

Frontiers in Immunology
IntroductionNeoantigens from the Kirsten rat sarcoma viral oncogene homolog (KRAS) are specific cancer therapeutic targets. However, to date, no immune product targeting KRAS neoantigens has been approved for clinical use, and key challenges regarding ...
Zhaoduan Liang, Zhaoduan Liang, Zhaoduan Liang, Fengqiong Guan, Bingling Wu, Wenfang Chen, Ye Tian, Wenxuan Cai, Yi Li, Yi Li, Yi Li   +10 more
doaj   +1 more source

Reconstitution of Lymphopaenic Mice with Regulatory and Conventional T cell Subsets

Bio-Protocol, 2016
Transfer of mature T cells into immunodeficient mice results in sub-optimal reconstitution of the peripheral T cell pool. Under lymphopenic conditions, dendritic cells are released from tonic control by regulatory T cells (Tregs), and consequently drive ...
Holly Bolton, Barbara Groth
doaj   +1 more source

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies

OncoImmunology, 2021
Based on the success of tumor-infiltrating lymphocytes (TIL)-based therapies, personalized adoptive cell therapies (ACT) targeting neoantigens have the potential to become a disruptive technology and lead to highly effective treatments for cancer ...
Florian Kast, Christian Klein, Pablo Umaña, Alena Gros, Stephan Gasser   +4 more
doaj   +1 more source